The Most Hotly Anticipated Ob/Gyn Research of 2014


New research expected this year will bring about significant changes to clinical practice. Here, society leaders share what’s on their radar for 2014.

New drugs, new research, new technology … there’s a lot for ob/gyns to look forward to in the coming year. Here, the leaders of five ob/gyn societies share the most interesting, important, exciting things on their radar for 2014.

(See what they thought was the most important research to come out of 2013 here.)


[[{"type":"media","view_mode":"media_crop","fid":"23567","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_5499654868617","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"1890","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"line-height: 1.538em; float: left; margin-left: 0px; margin-right: 0px;","title":" ","typeof":"foaf:Image"}}]]“Many more trials evaluating novel antitumor therapies will be reported in 2014. A big challenge is identifying methods to predict who is most likely to respond to these targeted therapies. Other anticipated studies are Gynecology Oncology Group studies (now part of NRG Oncology) evaluating the best therapy for upfront treatment of ovarian cancer. Specifically, intraperitoneal (IP) chemotherapy will be compared directly with dose-dense chemotherapy, which will help us establish what should be the new standard postoperative treatment for women who have been optimally cytoreduced.

“We should also hear if the combination of radiation and chemotherapy is superior to chemotherapy alone in the postoperative treatment of women with advanced endometrial cancer. Finally, we hope that the results of the UK ovarian cancer screening trial will be reported either in 2014 or 2015.”

- Barbara A. Goff, MD, President, Society of Gynecologic Oncology



[[{"type":"media","view_mode":"media_crop","fid":"23568","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_8970277262851","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"1891","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"line-height: 1.538em; float: left;","title":" ","typeof":"foaf:Image"}}]]“I’m looking forward to the results from the KEEPS trial and the ELITE trial, as well as more results from research on low libido.

- Margery Gass, MD, NCMP, Executive Director, The North American Menopause Society



[[{"type":"media","view_mode":"media_crop","fid":"23569","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_6041314275935","media_crop_h":"153","media_crop_image_style":"-1","media_crop_instance":"1912","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"350","media_crop_x":"0","media_crop_y":"84","style":"line-height: 1.538em; float: left; height: 87px; width: 200px;","title":" ","typeof":"foaf:Image"}}]]

“The results of the large (>15,000 participants) noninvasive prenatal testing (NIPT) ‘low-risk’ study, to see if we can start offering NIPT to all pregnant women.”

- Vincenzo Berghella, MD, President, Society of Maternal-Fetal Medicine


“The studies we’re waiting for in 2014 would be the results of the STAN study in the United States and the publication of the findings of a cervical pessary study conducted by the Fetal Medicine Foundation.”

- George R. Saade, MD, Past President, Society for Maternal-Fetal Medicine


[[{"type":"media","view_mode":"media_crop","fid":"23570","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_9292961589526","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"1895","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"line-height: 1.538em; float: left; height: 61px; width: 130px; border-style: solid;","title":" ","typeof":"foaf:Image"}}]]

“The results of the OPTIMAL trial, published in JAMA. This randomized trial, conducted by the Pelvic Floor Disorders Network, compared two types of vaginal native tissue repairs for apical prolapse and also compared the role of pelvic floor physical therapy on the outcomes, specifically stress urinary incontinence." (A synopsis of the OPTIMAL trial results is available here.)

“We will also be learning that the bladder may have more bacteria in it than we thought.”

- Charlie Nager, MD, President, American Urogynecologic Society



[[{"type":"media","view_mode":"media_crop","fid":"23571","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_3950970829464","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"1896","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"line-height: 1.538em; margin: 0px; float: left;","title":" ","typeof":"foaf:Image"}}]]“After Richard Scott, MD, of Reproductive Medicine Associates of New Jersey (RMANJ) showed successful pre-implantation genetic testing at the blastocyst stage, they are continuing their research by looking at whether pre-implantation genetic testing enables one to screen for embryos that will develop normally. Preliminary findings show that this does increase the live birth rate in women of advanced maternal age. We’re really interested in whether pre-implantation genetic testing improves the chances of live births. This finding is going to have a major impact on assistive reproductive technologies and IVF. We’re told the work has been done and is positive, but we haven’t seen any results in print yet.

“Another major finding to look forward to involves being able to assess the quality of embryos in order to select those that are normal and that are the best to put back into the recipient. This involves a procedure called time lapse imaging microscopy, which is getting a lot of attention. There is very good preliminary evidence that strongly suggest that embryos undergoing cell division at exact intervals are the ones that give rise to live births. I’ve been told a randomized controlled trial has been completed that confirmed these findings, and I suspect we’re going to see something shortly. As soon as these findings are published, I expect every single IVF clinic in the world will get this equipment. There is a possibility that it could dramatically improve the live birth rate, and several clinics have already purchased the equipment.”

- Andrew La Barbera, PhD, Scientific Director, American Society for Reproductive Medicine

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit:
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit:
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit:
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit:
Navigating vasomotor symptoms in breast cancer patients | Image Credit:
Fertility counseling for oncology patients | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.